This product is solely intended for research purposes as a chemical compound. Its designation permits its use exclusively for in vitro testing and laboratory experimentation. All information regarding this product provided on our website is purely educational. By law, any form of bodily introduction of this product into humans or animals is strictly prohibited. It should only be handled by professionals who are licensed and qualified. This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such.
In stock
MOTS-c
Swipe right to view full table →
Cost per milligram |
$3.58 – $4.55 |
Purity |
99.87% |
Certified Endotoxin-safe |
Yes |
Independently Tested |
Yes |
Peptide Partners Manufacturer Id: WF03
Batch Id: MC202512
Authors: Sandra García-Benlloch, Francisco Revert-Ros, Jose Rafael Blesa, Rafael Alis
Source: https://www.sciencedirect.com/science/article/pii/S0196978122001061
The study investigated the effect of MOTS-c on myogenesis in human (LHCN-M2) and murine (C2C12) myoblasts. The findings indicate that wild-type MOTS-c peptide enhances myotube formation, whereas a variant with a substitution at tyrosine 8 (Y8F) does not. Furthermore, wild-type MOTS-c, but not the Y8F peptide, was shown to counteract the interleukin-6 (IL-6)-induced reduction of nuclear myogenin. The proposed mechanism is that MOTS-c interacts with the STAT3 transcription factor via its putative SH2 binding motif (YIFY region), thereby reducing STAT3’s transcriptional activity and promoting myotube formation.
This research explored how a naturally occurring peptide called MOTS-c affects muscle cell development. Using muscle cells from both humans and mice, the scientists found that MOTS-c helps these cells to mature and form muscle fibers. They also discovered that a specific part of the MOTS-c molecule is crucial for this process. When this part was altered, the beneficial effect was lost. The study suggests that MOTS-c works by influencing a key protein (STAT3) involved in cell growth, which in turn enhances the formation of new muscle tissue. This could have implications for understanding and potentially treating muscle-related conditions.
Authors: Huanyu Lu, Linni Fan, Wenli Zhang, Guo Chen, An Xiang, Li Wang, Zifan Lu, Yue Zhai
Source: https://www.sciencedirect.com/science/article/pii/S2211124723015991
This study elucidates the molecular mechanism by which MOTS-c ameliorates nonalcoholic steatohepatitis (NASH). The research demonstrates that MOTS-c directly interacts with the BH3 domain of the antiapoptotic protein B-cell lymphoma-2 (Bcl-2). This interaction enhances Bcl-2 protein stability by suppressing its ubiquitination. In vitro experiments using a Bcl-2 inhibitor and adeno-associated virus (AAV)-mediated Bcl-2 knockdown confirmed that the protective effects of MOTS-c against NASH-induced mitochondrial dysfunction, inflammation, and fibrosis are dependent on Bcl-2 function. Metabolomic analysis further revealed that MOTS-c reverses NASH-induced mitochondrial metabolic deficiencies.
This research uncovers how a natural peptide called MOTS-c can help protect the liver from a serious condition called nonalcoholic steatohepatitis (NASH), which is a severe form of fatty liver disease. The scientists discovered that MOTS-c works by interacting with a protein called Bcl-2, which is known to prevent cell death. By binding to Bcl-2, MOTS-c makes it more stable and prevents it from being broken down by the cell. This action helps to restore normal function to the mitochondria, the powerhouses of the cells, and reduces the inflammation and scarring associated with NASH. In essence, MOTS-c acts as a guardian for liver cells, protecting them from the damage caused by this disease.
Authors: Hiroshi Kumagai, Su-Jeong Kim, Brendan Miller, et al.
Source: https://www.cell.com/iscience/fulltext/S2589-0042(24)02437-4
This study identifies protein kinase CK2 as a direct and functional target of MOTS-c. In vitro, cell-free systems demonstrated that MOTS-c directly binds to and activates CK2. This interaction is crucial for the metabolic effects of MOTS-c. The study also investigated a naturally occurring variant, K14Q MOTS-c, which showed reduced binding to CK2 and a concomitant lack of activation. This provides a molecular basis for the observed physiological effects, linking the in vitro findings to in vivo and clinical observations.
This research discovered that a small protein called MOTS-c works by directly switching on an enzyme called CK2. Using experiments in a test tube, the scientists showed that MOTS-c binds to CK2 and activates it. This is like a key fitting into a lock to turn on a machine. They also found that a common variation of the MOTS-c ‘key’ doesn’t fit the CK2 ‘lock’ as well, and so it can’t turn on the machine. This discovery helps to explain how MOTS-c affects our bodies at a molecular level, and why some people might be more prone to certain health issues.
Storage:
All of our manufacturing partners produce peptides using the Lyophilization (Freeze Drying) process, ensuring products maintain stability for shipping and storage for 12+ months.
In lyophilized form, they are shelf-stable for many weeks. However, for long-term storage, it is recommended to store them in the freezer.
We often hear concerns about the standard “discard after 28 days of first use” disclaimer. Don’t worry, this has nothing to do with studies regarding the efficacy of specific peptides. 28 days is the FDA requirement for producers of multi-use vials to prove their bacteriostatic maintains efficacy. This minimum requirement becomes the de facto standard.
In our experience, if you use proper sterile procedures and refrigerated storage, you can continue sampling from the same reconstituted vial for 3+ months.
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
| Peptide | Batch Id | Manufacturer | Date | Purity | Laboratory | |
|---|---|---|---|---|---|---|
| Tesamorelin | TES202601 | WF03 | 2025-12-29 | 99.71% | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2025-12-29 | 99.46% | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-29 | 99.64% | TrustPointe | View File |
| GHK-Cu | GK202512 | SH07 | 2025-12-19 | 99.79% | BioRegen | View File |
| MOTS-c | MC202512 | WF03 | 2025-12-22 | 99.89% | BioRegen | View File |
| Retatrutide | RP260130 | VI32 | 2025-12-22 | 99.72% | TrustPointe | View File |
| SS-31 | SS202512 | WF03 | 2025-12-19 | 99.7% | TrustPointe | View File |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | 99.63% | TrustPointe | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-09 | 99.80% | TrustPointe | View File |
| Retatrutide | RP202511 | DF05 | 2025-12-19 | 99.73% | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | 99.33% | TrustPointe | View File |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | 99.86% | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | 99.74% | TrustPointe | View File |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | 99.47% | TrustPointe | View File |
| Humanin | HP20250805 | WF03 | 2025-09-19 | 99.92% | BioRegen | View File |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | 99.87% | BioRegen | View File |
| DSIP | DS20250820 | SH07 | 2025-09-19 | 99.88% | BioRegen | View File |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | 99.70% | BioRegen | View File |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-11 | 99.84% | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-09-05 | 99.99% | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-08-27 | 99.84% | BioRegen | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-08-22 | 99.10% | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | 99.43% | TrustPointe | View File |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | 99.34% | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-08-15 | 99.64% | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-08-09 | 99.73% | BioRegen | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-08 | 99.41% | TrustPointe | View File |
| NAD+ | ND20250503 | SH07 | 2025-07-31 | 99.76% | BioRegen | View File |
| VIP | VP20250511 | SH07 | 2025-07-31 | 99.42% | BioRegen | View File |
| Retatrutide | CD20250708 | SH07 | 2025-07-25 | 99.42% | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | 99.52% | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | 99.68% | TrustPointe | View File |
| Peptide | Batch Id | Manufacturer | Date | USP Conformation | Laboratory | |
|---|---|---|---|---|---|---|
| Tesamorelin | TES202601 | WF03 | 2025-01-06 | Conforms | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| Retatrutide | RP260130 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| SS-31 | SS202512 | WF03 | 2025-12-19 | Conforms | TrustPointe | View File |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-08 | Conforms | TrustPointe | View File |
| Retatrutide | RP202511 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | Conforms | TrustPointe | View File |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | Conforms | TrustPointe | View File |
| Humanin | HP20250805 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| DSIP | DS20250820 | SH07 | 2025-09-19 | Conforms | BioRegen | View File |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| Bacteriostatic Water | BAC20250807 | SH07 | 2025-08-27 | Conforms | BioRegen | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-08-11 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-08-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-04 | Conforms | TrustPointe | View File |
| NAD+ | ND20250503 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| VIP | VP20250511 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| Retatrutide | CD20250708 | SH07 | 2025-07-24 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
| Peptide | Batch Id | Manufacturer | Date | USP Conformation | Laboratory | |
|---|---|---|---|---|---|---|
| BPC-157 | BP202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-12-03 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-24 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-12 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| SS-31 | SY20250806 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-11-12 | Conforms | TrustPointe | View File |
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
USP <85> Spike CV %:
USP <85> Spike Recovery
Thank you for choosing Peptide Partners.
NOTICE: All information provided above is strictly intended for educational and informational purposes. Our products are designed for research use solely and are not approved for human consumption. Please refrain from any form of ingestion.
By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals. Our products are exclusively intended for laboratory research purposes.
It is imperative that only qualified and licensed professionals handle this product. Under no circumstances should it be utilized as a drug, agricultural or pesticide product, food additive, or household chemical. Misrepresentation of this product for such purposes is strictly prohibited by law. All content on our website is provided for educational use exclusively. Any form of introduction into the human or animal body is illegal.